Health Care [ 4/12 ] | Biotechnology [ 20/74 ]
NASDAQ | Common Stock
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial.
In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks.
The company is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 10, 25 | -0.92 Decreased by -9.52% | -0.87 Decreased by -6.02% |
| Dec 5, 24 | -0.91 Decreased by -13.75% | -0.91 |
| Sep 5, 24 | -0.87 Decreased by -17.57% | -0.91 Increased by +4.40% |
| Jul 11, 24 | -1.02 Decreased by -32.47% | -0.73 Decreased by -39.73% |
| Mar 11, 24 | -0.84 Decreased by -12.00% | -0.77 Decreased by -9.09% |
| Dec 7, 23 | -0.80 Increased by +11.11% | -0.79 Decreased by -1.27% |
| Sep 7, 23 | -0.74 Increased by +21.28% | -0.86 Increased by +13.95% |
| Jul 7, 23 | -0.77 Increased by +21.43% | -0.94 Increased by +18.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jan 31, 25 | 0.00 Decreased by N/A% | -48.51 M Decreased by -67.11% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 24 | 0.00 Decreased by N/A% | -42.27 M Decreased by -52.87% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 24 | 0.00 Decreased by N/A% | -40.44 M Decreased by -59.75% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 24 | 1.21 M Increased by +N/A% | -44.65 M Decreased by -11.53% | Decreased by -3.70 K% Decreased by N/A% |
| Jan 31, 24 | 0.00 Decreased by N/A% | -29.03 M Decreased by -102.54% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 23 | 0.00 Decreased by N/A% | -27.65 M Decreased by -49.47% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 23 | 0.00 Decreased by N/A% | -25.32 M Decreased by -9.87% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 23 | 0.00 Decreased by N/A% | -40.03 M Decreased by -80.70% | Decreased by N/A% Decreased by N/A% |